Table 1 Baseline characteristics of eyes with myopic choroidal neovascularization
Parameter | Total eyes (n = 51) |
|---|---|
Age (years) | 53.88 ± 14.01 |
Gender (n, %) | |
Female | 38 (74.5%) |
Male | 13 (25.5%) |
Refractive error (D) | − 12.46 ± 3.12 |
BCVA (logMAR) | 0.70 (0.40–1.30) |
Anti-VEGF (n, %) | |
Ranibizumab | 28 (54.9%) |
Conbercept | 23 (45.1%) |
Number of initial injections | 2 (1–3) |
Number of total injections | 3 (2–4) |
Follow-up duration (months) | 27 (20–41) |
CNV location (n, %) | |
Subfoveal | 33 (64.7%) |
Parafoveal | 18 (35.3%) |
CNV area (mm2) | 0.361 (0.180–0.897) |
CNV flow area (mm2) | 0.299 (0.136–0.646) |
CNV pattern (n, %) | |
“Medusa”: “Seafan”: “indistinct network” | 22:8:21 (43.1%:15.7%:41.2%) |
PSV (n, %) | 51 (100.0%) |
Lacquer cracks (n, %) | 16 (31.4%) |
Posterior staphyloma (n, %) | 45 (88.2%) |
Retinoschisis (n, %) | 14 (27.5%) |
Dilated choroidal vein (n, %) | 17 (33.3%) |
Hyperreflective area height (µm) | 210 (170–286) |
Central foveal thickness (µm) | 300 (219–381) |
Subfoveal choroidal thickness (µm) | 54 (26–72) |